Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
La Jolla Institute for Immunology maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are currently 7 pending office actions being handled by 7 distinct examiners. This one-to-one ratio between actions and examiners suggests a highly diversified prosecution landscape where no two pending matters are being reviewed by the same person. The involvement of 5 distinct art units further indicates that the institute's intellectual property covers a range of biological or pharmaceutical disciplines, requiring a broad technical strategy.
The busiest examiner, BOESEN, AGNIESZKA, is responsible for 1 pending office action. Given that the total count of pending office actions is 7, the workload is perfectly distributed among the 7 distinct examiners. This lack of concentration means that the institute must manage 7 independent prosecution timelines and examiner relationships. Practitioners should be aware that the strategies employed for the 1 pending office action under the busiest examiner may have limited relevance to the others due to the diversity of the examining staff.
The presence of 5 distinct art units for 7 examiners implies that multiple examiners are likely operating within the same art unit. Specifically, with 7 distinct examiners spread across 5 distinct art units, there is a concentration of expertise within certain units even as the examiners themselves remain distinct. This environment requires a coordinated approach to ensure that arguments made in one of the 5 art units remain consistent with those made in the others. The busiest examiner's load of 1 pending action reflects this balanced distribution across the 7 total pending matters.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (40%) |
| §112 only | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOESEN, AGNIESZKA | 1 | 68.6% | +21.8% |
| KIRWIN, STEFANIE JOHANNA | 1 | 15.6% | +29.6% |
| LOCKARD, JON MCCLELLAND | 1 | 74.4% | +27.4% |
| XIAO, YAN | 1 | 67.3% | +52.7% |
| GONZALES, JOSEPHINE MARIA | 1 | 28.8% | +34.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16765783 | USE AND PRODUCTION OF ENGINEERED IMMUNE CELLS TO DISRUPT NFAT-AP1 PATHWAY TRANSCRIPTION FACTORS | GONZALES, JOSEPHINE MARIA | 4d overdue |
| 18016538 | Methods and Compositions for Diagnosing and Treating Cancer | KIRWIN, STEFANIE JOHANNA | 65d |
| 18700922 | ENGINEERED RABIES VIRUS GLYCOPROTEIN, COMPOSITIONS, AND METHODS OF USE THEREOF | BOESEN, AGNIESZKA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16765783 | USE AND PRODUCTION OF ENGINEERED IMMUNE CELLS TO DISRUPT NFAT-AP1 PATHWAY TRANSCRIPTION FACTORS | GONZALES, JOSEPHINE MARIA | 4d overdue |
| 18016538 | Methods and Compositions for Diagnosing and Treating Cancer | KIRWIN, STEFANIE JOHANNA | 65d |
| 18700922 | ENGINEERED RABIES VIRUS GLYCOPROTEIN, COMPOSITIONS, AND METHODS OF USE THEREOF | BOESEN, AGNIESZKA | — |
| 17916548 | METHODS AND COMBINATIONS FOR DUAL TARGETING OF TNF FAMILY MEMBERS | LOCKARD, JON MCCLELLAND | — |
| 17779392 | Methods and Compositions for Modulationg Heterochromatin Dysfunction, Genomic Instability, and Associate Conditions | XIAO, YAN | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| 1677 | 1 |
| 1647 | 1 |
| 1642 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18700922 | ENGINEERED RABIES VIRUS GLYCOPROTEIN, COMPOSITIONS, AND METHODS OF USE THEREOF | BOESEN, AGNIESZKA | 1672 | §101§102§112 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18016538 | Methods and Compositions for Diagnosing and Treating Cancer | KIRWIN, STEFANIE JOHANNA | 1677 | §101§103§112 | Non-Final OA | 65d | Pending | Jan 17, 2023 |
| 17916548 | METHODS AND COMBINATIONS FOR DUAL TARGETING OF TNF FAMILY MEMBERS | LOCKARD, JON MCCLELLAND | 1647 | §112 | Non-Final OA | — | Pending | Sep 30, 2022 |
| 17779392 | Methods and Compositions for Modulationg Heterochromatin Dysfunction, Genomic Instability, and Associate Conditions | XIAO, YAN | 1642 | §112 | Non-Final OA | — | Pending | May 24, 2022 |
| 16765783 | USE AND PRODUCTION OF ENGINEERED IMMUNE CELLS TO DISRUPT NFAT-AP1 PATHWAY TRANSCRIPTION FACTORS | GONZALES, JOSEPHINE MARIA | 1631 | §112 | Non-Final OA | 4d overdue | Pending | May 20, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLa Jolla Institute for Immunology has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Agnieszka Boesen has the most, with 1 of La Jolla Institute for Immunology's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
